ZA948541B - Endothelin receptor antagonists - Google Patents

Endothelin receptor antagonists

Info

Publication number
ZA948541B
ZA948541B ZA948541A ZA948541A ZA948541B ZA 948541 B ZA948541 B ZA 948541B ZA 948541 A ZA948541 A ZA 948541A ZA 948541 A ZA948541 A ZA 948541A ZA 948541 B ZA948541 B ZA 948541B
Authority
ZA
South Africa
Prior art keywords
receptor antagonists
endothelin receptor
endothelin
antagonists
receptor
Prior art date
Application number
ZA948541A
Other languages
English (en)
Inventor
Hideyuki Saika
Toshiki Murata
Thomas Pitterna
Thomas Frueh
Lene D Svensson
Yoshihiro Urade
Takaki Yamamura
Toshikazu Okada
Original Assignee
Japat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japat Ltd filed Critical Japat Ltd
Publication of ZA948541B publication Critical patent/ZA948541B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA948541A 1993-11-01 1994-10-31 Endothelin receptor antagonists ZA948541B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93810760 1993-11-01

Publications (1)

Publication Number Publication Date
ZA948541B true ZA948541B (en) 1995-05-02

Family

ID=8215056

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA948541A ZA948541B (en) 1993-11-01 1994-10-31 Endothelin receptor antagonists

Country Status (12)

Country Link
US (1) US5780498A (fr)
EP (1) EP0728145A1 (fr)
JP (1) JPH09504302A (fr)
AU (1) AU691201B2 (fr)
BR (1) BR9407933A (fr)
CA (1) CA2173875A1 (fr)
FI (1) FI961804A (fr)
IL (1) IL111431A0 (fr)
NO (1) NO961725D0 (fr)
RU (1) RU2126418C1 (fr)
WO (1) WO1995012611A1 (fr)
ZA (1) ZA948541B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033170A1 (fr) * 1995-04-21 1996-10-24 Novarits Ag Amides de n-aroylaminoacide utilises en tant qu'inhibiteurs d'endotheline
AU7130296A (en) * 1995-09-28 1997-04-17 Ciba-Geigy Japan Limited Antagonists of endothelin receptors
IT1291823B1 (it) * 1997-04-08 1999-01-21 Menarini Ricerche Spa Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
GB9708119D0 (en) * 1997-04-22 1997-06-11 Glaxo Group Ltd Chemical compounds
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
DE19745146A1 (de) 1997-10-14 1999-04-15 Basf Ag Neue pharmazeutisch wirksame Verbindungen, ihre Herstellung und Verwendung
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6191171B1 (en) 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
US6090841A (en) * 1997-11-21 2000-07-18 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6426354B1 (en) 1998-04-23 2002-07-30 Novartis Ag Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
EP1073674A1 (fr) * 1998-04-23 2001-02-07 Novartis AG Certains inhibiteurs thiol d'une enzyme de conversion d'endotheline
US6423727B1 (en) 1998-04-23 2002-07-23 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
CA2360740A1 (fr) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
SI1178958T1 (en) * 1999-03-15 2004-08-31 Axys Pharmaceuticals, Inc. N-cyanomethyl amides as protease inhibitors
KR100679878B1 (ko) * 1999-04-26 2007-02-07 아지노모토 가부시키가이샤 멜라노사이트-자극 호르몬 억제제
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
WO2002100846A1 (fr) * 2001-06-11 2002-12-19 Shire Biochem Inc. Composes et methodes de traitement ou de prevention d'infections a flavivirus
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
CA2505098A1 (fr) 2002-11-12 2004-05-27 Merck & Co., Inc. Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
WO2005014534A1 (fr) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Composes aryle et heteroaryle, compositions, et methodes d'utilisation
WO2005014533A2 (fr) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Composes aryle et heteroaryle, compositions et procedes d'utilisation
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
GB0514071D0 (en) * 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
US20090012010A1 (en) * 2007-05-18 2009-01-08 Neuromed Phramaceuticals Ltd. Amino acid derivatives as calcium channel blockers
KR20130004579A (ko) * 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US9260427B2 (en) * 2013-06-11 2016-02-16 Receptos, Inc. GLP-1 receptor modulators
WO2015106242A2 (fr) * 2014-01-13 2015-07-16 The General Hospital Corporation Composés bisamide utilisés comme effecteurs allostériques pour réduire l'affinité de liaison de l'hémoglobine pour l'oxygène
US10758569B2 (en) 2014-01-13 2020-09-01 The General Hospital Corporation Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin
US10829440B2 (en) * 2015-06-12 2020-11-10 Brown University Antibacterial compounds and methods of making and using same
CN108821994A (zh) * 2018-05-24 2018-11-16 三峡大学 一类双羟基酰氧基双酰胺类药物中间体及其制备方法
US11555010B2 (en) 2019-07-25 2023-01-17 Brown University Diamide antimicrobial agents
RU2716258C1 (ru) * 2019-07-30 2020-03-11 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Пептидный антагонист нмда-рецептора
EP4165037A1 (fr) 2020-06-10 2023-04-19 Aligos Therapeutics, Inc. Composés antiviraux pour le traitement d'infections à coronavirus, picornavirus et norovirus
FR3111544A1 (fr) * 2020-06-18 2021-12-24 Universite Paris-Saclay Nouveaux composés dipeptidiques, leur procédé de fabrication et une nouvelle application thérapeutique de composés dipeptidiques.
RU2769051C1 (ru) * 2021-06-30 2022-03-28 Общество с ограниченной ответственностью "ТЕРРАНОВА КАПИТАЛ" Пептид, улучшающий функциональные свойства эндотелия сосудов, фармацевтическая композиция на его основе и способ ее применения
KR20240035513A (ko) 2021-07-09 2024-03-15 알리고스 테라퓨틱스 인코포레이티드 항바이러스 화합물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623142B2 (fr) * 1974-07-01 1981-05-29
US4025644A (en) * 1974-12-18 1977-05-24 Daiichi Seiyaku Co., Ltd. Tyrosine derivatives and use
DE2901667A1 (de) * 1979-01-17 1980-07-31 Troponwerke Gmbh & Co Kg Pharmazeutische verwendung von dipeptiden
EP0072058A1 (fr) * 1981-08-10 1983-02-16 Duphar International Research B.V Seringue à compartiments multiples
US4395401A (en) * 1981-09-09 1983-07-26 Smithkline Beckman Corporation Renally active dipeptides
JPS58133260A (ja) * 1982-02-02 1983-08-08 河村　純郎 多段注射器
DE3332633A1 (de) * 1983-09-09 1985-04-04 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Substituierte carbonsaeurederivate, verfahren zu ihrer herstellung, und arzneimittel
AU589665B2 (en) * 1985-08-14 1989-10-19 G.D. Searle & Co. Substituted dipeptide amides
CA1297633C (fr) * 1985-09-27 1992-03-17 Shosuke Okamoto Derive phenylalamine et inhibiteur de la proteinase
ES2017924B3 (es) * 1985-10-11 1991-03-16 Duphar Int Res B V Inyector automatico.
DE3770294D1 (de) * 1986-03-14 1991-07-04 Syntex Inc 3,5-disubstituierte 4,5-dihydroisoxazole als transglutaminasehemmer.
US5187156A (en) * 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
CA1326108C (fr) * 1988-04-12 1994-01-11 Sun Hyuk Kim Antagoniste de la cck
JPH0347163A (ja) * 1989-06-30 1991-02-28 Fujisawa Pharmaceut Co Ltd アントラキノン誘導体およびその製造
CA2032559C (fr) * 1989-12-28 2001-11-06 Kiyofumi Ishikawa Pentapeptides cycliques antagonistes de l'endotheline
US5284828A (en) * 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
CA2043741C (fr) * 1990-06-07 2003-04-01 Kiyofumi Ishikawa Derives de peptides antagonistes d'endotheline
DK220890D0 (da) * 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
EP0668770A1 (fr) * 1991-04-24 1995-08-30 Warner-Lambert Company POLYPEPTIDES $g(a) SUBSTITUES AYANT DES PROPRIETES THERAPEUTIQUES
TW270116B (fr) * 1991-04-25 1996-02-11 Hoffmann La Roche
DE69231404T2 (de) * 1991-05-16 2001-02-08 Warner Lambert Co Endothelinantagonisten
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
RO117847B1 (ro) * 1991-11-05 2002-08-30 Smithkline Beecham Corp Derivati de indan, procedeu de preparare, compozitie farmaceutica care ii contine si metoda de tratament
TW224462B (fr) * 1992-02-24 1994-06-01 Squibb & Sons Inc
US5550138A (en) * 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
WO1994002474A1 (fr) * 1992-07-17 1994-02-03 Smithkline Beecham Corporation Antagonistes du recepteur de l'endotheline

Also Published As

Publication number Publication date
NO961725L (no) 1996-04-29
NO961725D0 (no) 1996-04-29
CA2173875A1 (fr) 1995-05-11
BR9407933A (pt) 1996-11-26
EP0728145A1 (fr) 1996-08-28
WO1995012611A1 (fr) 1995-05-11
FI961804A (fi) 1996-04-30
AU691201B2 (en) 1998-05-14
JPH09504302A (ja) 1997-04-28
AU7856594A (en) 1995-05-23
IL111431A0 (en) 1994-12-29
RU2126418C1 (ru) 1999-02-20
US5780498A (en) 1998-07-14
FI961804A0 (fi) 1996-04-26

Similar Documents

Publication Publication Date Title
IL111431A0 (en) Endothelin receptor antagonists
ZA939516B (en) Endothelin receptor antagonists
EP0763035A4 (fr) Antagonistes du recepteur de l'endotheline
HK1012251A1 (en) Endothelin receptor antagonists
AU4679793A (en) Endothelin receptor antagonists
SG49667A1 (en) Endothelin receptor antagonists
ZA969775B (en) Endothelin receptor antagonists.
EP0574530A4 (en) Endothelin antagonists
EP0766684A4 (fr) Antagonistes du recepteur de l'endotheline
HU9602054D0 (en) Endothelin receptor antagonists
HUP9902817A3 (en) Endothelin receptor antagonists
EP0854721A4 (fr) Antagonistes des recepteurs a l'endotheline
ZA966552B (en) Endothelin receptor antagonists.
EP0768878A4 (fr) Antagonistes des recepteurs de l'endotheline
EP0841926A4 (fr) Antagonistes du recepteur d'endotheline
EP0711157A4 (fr) Antagonistes du recepteur d'endotheline
EP0841916A4 (fr) Antagonistes du recepteur d'endotheline
EP0868180A4 (fr) Antagonistes du recepteur d'endotheline
GB9318105D0 (en) Receptor action
ZA957308B (en) Endothelin receptor antagonists
SG64880A1 (en) Endothelin receptor antagonists
ZA966592B (en) Endothelin receptor antagonists
GB9100721D0 (en) Endothelin antagonists
GB9510203D0 (en) Novel endothelin receptor antagonists
ZA928467B (en) Endothelin receptor antagonists.